Home > Riviste > Minerva Urology and Nephrology > Fascicoli precedenti > Minerva Urologica e Nefrologica 2020 April;72(2) > Minerva Urologica e Nefrologica 2020 April;72(2):214-22

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE   Free accessfree

Minerva Urologica e Nefrologica 2020 April;72(2):214-22

DOI: 10.23736/S0393-2249.19.03377-0

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

Circulating tumor cells as prognostic biological marker in different stages prostate cancer and the effect of different therapeutic approaches on their expression

Giuseppe PALERMO 1 , Pierfrancesco BASSI 1, Marco RACIOPPI 1, Salvatore M. RECUPERO 1, Emilio SACCO 1, Marco CAMPETELLA 1, Giulia CANU 2, Francesco PINTO 1

1 Department of Urology, A. Gemelli University Polyclinic, IRCCS and Foundation, Rome, Italy; 2 Department of Biochemistry, A. Gemelli University Polyclinic, IRCCS and Foundation, Rome, Italy



BACKGROUND: Circulating tumor cells (CTCs) represent a prerequisite for the formation of metastases. The aim of the study was to identify the role of CTCs as a biological marker of aggressiveness of prostate cancer and verify the expression of molecular markers predictive of response to different therapeutic approaches.
METHODS: Prospective, single-arm, non-randomized trial. Twenty-four patients with prostate cancer were enrolled into two groups: group 1 (N.=11) with localized prostate cancer treated with radical prostatectomy; group 2 (N.=13) with metastatic disease. We performed, dosage of blood PSA and testosterone, detection of EGFR, PSMA, PSA and Androgen Receptor (AR) expression on CTC during pre-treatment and follow-up at 1, 3, 9 and 18 months.
RESULTS: A total of 65 blood samples were evaluated. In group 1, pre-treatment sampling was negative for the expression of markers on CTC in 90% of the patients while group 2 pre-treatment sampling was positive for the expression of at least one biomarker in seven of 13 patients (54%). After treatment, four patients in group 2 experienced a reduced expression of the markers on CTC, however, in one case there was a new increase of PSA and PSMA at 3 months. One patient had a positivity of AR at 3 months.
CONCLUSIONS: The expression of PSA, PSMA, EGFR and AR on CTCs appears to be absent in the pre-treatment samplings in cases of localized prostate cancer. The same markers are hyper-expressed before treatment mostly in metastatic prostate cancer and can relate with early biochemical relapse.


KEY WORDS: Circulating neoplastic cells; Prostatic neoplasms; Biomarkers

inizio pagina